# Quercetin Phytosome (Quercefit®)

> Quercetin Phytosome is quercetin, a natural antihistamine flavonoid, wrapped in a phospholipid carrier that solves quercetin's biggest limitation: terrible absorption. Plain quercetin runs 1-2% bioavailable; Indena's branded Quercefit form delivers about 20 times more quercetin into the bloodstream per milligram, achieving levels relevant for MCAS mast cell stabilization. ZebraThrive uses 300 mg daily in the powder.

**Page:** https://www.wellnessforzebras.com/ingredients/quercetin-phytosome
**Brand:** ZebraThrive
**Author:** Ken Chapman, Founder of ZebraThrive
**Last reviewed:** 2026-05-11
**Daily dose:** 300 mg (Daily Powder)
**Form used:** Quercefit® (Indena quercetin phytosome) - v7.8 mandatory-branded sourcing
**Target population:** Adults 18+ with hypermobile Ehlers-Danlos Syndrome (hEDS), Postural Orthostatic Tachycardia Syndrome (POTS), or Mast Cell Activation Syndrome (MCAS).
**Regulatory framing:** US DSHEA dietary supplement. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

## Key benefits

- ~20x higher bioavailability than plain quercetin (plain runs 1-2%, Quercefit phospholipid carrier hits clinical-grade levels)
- Mast cell stabilization matched or beat cromolyn across histamine, prostaglandins, leukotrienes, TNF, and IL-8 in head-to-head testing
- Engages MRGPRX2 via CLM-1 - the non-IgE pathway that drives many MCAS reactions to medications and contrast dyes
- v7.8 mandatory-branded sourcing (Indena Quercefit® is the only quercetin form with the 20x human PK data)

## What it is

Quercetin Phytosome is quercetin - the flavonoid known as a natural antihistamine - wrapped in a phospholipid carrier that solves quercetin's biggest problem: terrible absorption.

## Why we include it

Plain quercetin has bioavailability around 1-2%. Quercefit® (Indena's branded phytosome form) delivers about 20 times more quercetin into your bloodstream per milligram.

## Plain-language summary

Quercetin Phytosome is quercetin - the flavonoid known as a natural antihistamine - wrapped in a phospholipid carrier that solves quercetin's biggest problem: terrible absorption. Plain quercetin has bioavailability around 1-2%. Quercefit® (Indena's branded phytosome form) delivers about 20 times more quercetin into your bloodstream per milligram. For MCAS, quercetin is one of the most-studied natural mast cell stabilizers - in head-to-head testing against cromolyn, quercetin matched or beat cromolyn across histamine, prostaglandins, leukotrienes, TNF, and IL-8 release. The phytosome form is the only way to get clinically meaningful quercetin levels at a reasonable dose.

## Mechanism

Quercetin Phytosome is quercetin - the flavonoid known as a natural antihistamine - wrapped in a phospholipid carrier that solves quercetin's biggest problem: terrible absorption. Plain quercetin has bioavailability around 1-2%. Quercefit® (Indena's branded phytosome form) delivers about 20 times more quercetin into your bloodstream per milligram. For MCAS, quercetin is one of the most-studied natural mast cell stabilizers - in head-to-head testing against cromolyn, quercetin matched or beat cromolyn across histamine, prostaglandins, leukotrienes, TNF, and IL-8 release. The phytosome form is the only way to get clinically meaningful quercetin levels at a reasonable dose.

## Condition-specific notes

### MCAS (Mast Cell Activation Syndrome)

Quercefit® delivers quercetin to your bloodstream at concentrations that actually engage the mast cell stabilization mechanisms. In side-by-side testing with cromolyn, quercetin matched or beat cromolyn across histamine, PGD2, leukotrienes, TNF, and IL-8 release. It also doesn't develop tachyphylaxis - the rapid loss of effect that limits cromolyn over time. A newer mechanism gets it even closer to home for MCAS: quercetin binds CLM-1 to suppress MRGPRX2-mediated degranulation, the non-IgE pathway that drives many MCAS reactions to medications and contrast dyes. Quercefit gives you actual clinical-grade quercetin levels at a swallowable dose.

### hEDS (hypermobile Ehlers-Danlos Syndrome)

Quercefit has the most direct hEDS-relevant collagen data of any ingredient in the formulation. A 2023 study in human uterosacral ligament fibroblasts showed quercetin reduced MMP-1, increased LOX (the cross-linking enzyme), and raised fibrillin-2 expression. A 2025 rat tendon study showed oral quercetin improved every measured biomechanical parameter of healing tendons - failure load, stiffness, ultimate stress, strain. At achievable Quercefit concentrations, quercetin sits in the pro-collagen, MMP-inhibiting range (the dose-response goes anti-fibrotic only at much higher concentrations not reached orally). An unusually well-aligned ingredient for hEDS.

### POTS (Postural Orthostatic Tachycardia Syndrome)

For POTS, Quercefit's relevance is mostly the mast cell layer that overlaps with so many POTS cases. A small human trial showed quercetin improved endothelial function (the responsiveness of the lining of your blood vessels), which could theoretically reduce blood pooling. The strongest documented POTS-relevant case is a 2021 published case report of a post-COVID POTS+MCAS patient who recovered from bed-bound to 85-90% of baseline on quercetin therapy. That's one case, not a trial - but the mechanism map (mast cells, vascular endothelium, anti-inflammatory) lines up with what POTS pathology looks like.

## Why this form

**Selected form:** Quercefit® (Indena quercetin phytosome) - v7.8 mandatory-branded sourcing

We use Quercefit® - Indena's quercetin phytosome - because it's the only quercetin form with human pharmacokinetic studies showing 20× higher bioavailability than plain quercetin. The phospholipid carrier (sunflower-derived lecithin, MCAS-safe) wraps the quercetin in a structure your gut absorbs efficiently. This is one of the few cases where the branded form is genuinely non-negotiable - generic 'quercetin phytosome' blends typically achieve only 1.5-2× the absorption of standard quercetin, far below Quercefit's 20× number. Quercefit® is the one mandatory branded sourcing in our formulation. Spec verified by Certificate of Analysis on every batch.

## Evidence summary

### Quercefit® Phytosome Bioavailability

The Indena Quercefit® phytosome delivery system delivers about 20x higher quercetin plasma concentrations than plain quercetin per milligram. Free quercetin half-life is short (~3.4-3.8 hours), so steady dosing matters; conjugated quercetin (the form actually circulating) persists longer.

- [1] **Riva A et al., "Improved Oral Absorption of Quercetin from Quercetin Phytosome®, a New Delivery System Based on Food Grade Lecithin".** Design: Human pharmacokinetic study, healthy volunteers. Finding: Quercefit® delivers approximately 20-fold higher quercetin absorption per milligram vs plain quercetin; free quercetin t½ measured 3.4-3.8 hours. PMID: 30328058.

### Allergic Rhinitis (Symptom Reduction)

Quercetin Phytosome formulations have human RCT evidence in allergic rhinitis, a closely-related histamine-driven condition with similar pathophysiology to MCAS.

- [2] **Yamada S et al., "Effects of repeated oral intake of a quercetin-containing supplement on allergic reaction: a randomized, placebo-controlled, double-blind study".** Design: Randomized double-blind placebo-controlled trial, n=66, Japan. Finding: Quercetin Phytosome at 200 mg/day significantly improved allergic rhinitis symptoms vs placebo over the trial period. PMID: 35776034.

### Clinical Application (Post-Viral Inflammation)

Quercetin Phytosome has been evaluated in randomized clinical trials for early-stage COVID-19, which shares with MCAS and post-viral POTS a mast-cell/cytokine-driven inflammatory pathophysiology.

- [3] **Di Pierro F et al., "Quercetin as a possible complementary agent for early-stage COVID-19: Concluding results of a randomized clinical trial".** Design: Randomized clinical trial, early-stage COVID-19. Finding: Quercefit® supplementation accelerated symptom resolution and reduced inflammatory markers in early-stage COVID-19 patients. PMID: 36712674.
- [4] **Di Pierro F et al., "Potential Clinical Benefits of Quercetin in the Early Stage of COVID-19: Results of a Second, Pilot, Randomized, Controlled and Open-Label Clinical Trial".** Design: Randomized controlled open-label trial, n=42. Finding: Quercefit® reduced time to molecular conversion to SARS-CoV-2 negative; LDH -35.5%, Ferritin -40%, CRP -54.8%, D-dimer -11.9% vs standard of care. PMID: 34194240.

## Safety

**Side effects:** Quercefit shows excellent tolerability in 15+ human clinical studies. Plain quercetin causes paradoxical reactions in 10-15% of MCAS patients (one reason luteolin is often preferred for high-sensitivity profiles); Quercefit has fewer reported paradoxical reactions due to the different delivery vehicle, but the pattern can still occur.

**Interactions:** Quercetin is a CYP3A4 inhibitor in lab tests; recent human data shows repeated dosing produces CYP3A4 induction (not inhibition) via the PXR receptor, downgrading the ivabradine concern to LOW-MODERATE. For metoprolol and propranolol (CYP2D6 substrates), in vivo human data is mixed; start at standard dose and monitor. Mention to your prescriber when initiating.

**Excipients to avoid:** Soy-derived lecithin carriers (Quercefit uses sunflower lecithin, MCAS-safe), Magnesium stearate, Artificial colors

**Excipients that are safe:** Sunflower lecithin phospholipid carrier, HPMC capsules, Rice flour

## Frequently asked questions

### Why mandatory Quercefit® instead of generic quercetin phytosome?

The bioavailability difference is real and dramatic. Quercefit® has the human PK study showing 20× absorption - generic 'quercetin phytosome' blends typically deliver 1.5-2× absorption at best. The phytosome technology requires a specific manufacturing process to produce a true phospholipid-quercetin complex; simple mixing doesn't replicate it. For an ingredient where bioavailability is the entire point of paying a premium, the branded form is the only one that delivers on the claim. This is the one mandatory brand in our formulation.

### How is Quercefit different from EMIQ or plain quercetin?

All three deliver quercetin to your body, but the mechanisms differ. Plain quercetin is barely absorbed (1-2%). EMIQ uses an enzymatic glucose tag to lift absorption about 17-fold. Quercefit uses a phospholipid carrier to lift absorption about 20-fold. EMIQ and Quercefit are similar magnitudes of bioavailability boost - the carrier chemistry differs. Quercefit has 15 human clinical studies across allergic rhinitis, exercise recovery, and COVID-19 - the deepest clinical literature of any enhanced quercetin form.

### Is Quercefit safe with ivabradine and beta-blockers?

This was a longstanding question, and recent human data has clarified it. Quercetin is a CYP3A4 inhibitor in lab tests, but repeated dosing in humans produces CYP3A4 induction (not inhibition) via the PXR receptor. The risk for ivabradine has been downgraded to LOW-MODERATE. For metoprolol and propranolol (CYP2D6 substrates), in vivo data is mixed. The cautious approach is to start at standard dose, monitor your medications normally, and mention quercetin to your prescriber.

### How long until I notice anything from Quercefit?

For mast cell stabilization, the same rules apply as with other natural stabilizers: most people who respond notice changes in 4-8 weeks of consistent dosing, with the clinical trials running 2-6 months. The big difference with Quercefit is that you actually reach mast-cell-active concentrations at a normal supplement dose - plain quercetin often doesn't, which is why people try quercetin and feel nothing. Daily consistency is the unlock; the bioavailability is the prerequisite.

## References

[1] Riva A et al.. (2019). Improved Oral Absorption of Quercetin from Quercetin Phytosome®, a New Delivery System Based on Food Grade Lecithin. PMID: 30328058. https://pubmed.ncbi.nlm.nih.gov/30328058/
[2] Yamada S et al.. (2022). Effects of repeated oral intake of a quercetin-containing supplement on allergic reaction: a randomized, placebo-controlled, double-blind study. PMID: 35776034. https://pubmed.ncbi.nlm.nih.gov/35776034/
[3] Di Pierro F et al.. (2023). Quercetin as a possible complementary agent for early-stage COVID-19: Concluding results of a randomized clinical trial. PMID: 36712674. https://pubmed.ncbi.nlm.nih.gov/36712674/
[4] Di Pierro F et al.. (2021). Potential Clinical Benefits of Quercetin in the Early Stage of COVID-19: Results of a Second, Pilot, Randomized, Controlled and Open-Label Clinical Trial. PMID: 34194240. https://pubmed.ncbi.nlm.nih.gov/34194240/